-transparent.png){kind=logo}
One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13%), in 25 patients with colorectal carcinoma (partial response, 16%), and in 6 patients with renal cell carcinoma (partial response, 50%). Two partial responses occurred in 15 patients with squamous cancer. No significant responses were seen in 27 patients with other adenocarcinomas, 13 with sarcomas, 14 with melanomas, and 8 with miscellaneous tumors. The most frequent toxicities were dermatitis, stomatitis, gastrointestinal symptoms, and mild myelosuppression. The incidence of dermatitis was significantly decreased by shortening the schedule of Baker's Antifol administration from 5 to 3 days. Baker's Antifol has some degree of antitumor activity, and studies of combination of this agent with other effective chemotherapeutic agents are indicated.
V Rodriguez, and
S P Richman, and
R S Benjamin, and
M A Burgess, and
W K Murphy, and
M Valdivieso, and
R L Banner, and
J U Gutterman, and
G P Bodey, and
E J Freireich
January 1981,
Cancer treatment reports,
V Rodriguez, and
S P Richman, and
R S Benjamin, and
M A Burgess, and
W K Murphy, and
M Valdivieso, and
R L Banner, and
J U Gutterman, and
G P Bodey, and
E J Freireich
April 1978,
Cancer treatment reports,
V Rodriguez, and
S P Richman, and
R S Benjamin, and
M A Burgess, and
W K Murphy, and
M Valdivieso, and
R L Banner, and
J U Gutterman, and
G P Bodey, and
E J Freireich
August 1976,
Cancer,
V Rodriguez, and
S P Richman, and
R S Benjamin, and
M A Burgess, and
W K Murphy, and
M Valdivieso, and
R L Banner, and
J U Gutterman, and
G P Bodey, and
E J Freireich
November 1977,
Cancer treatment reports,
V Rodriguez, and
S P Richman, and
R S Benjamin, and
M A Burgess, and
W K Murphy, and
M Valdivieso, and
R L Banner, and
J U Gutterman, and
G P Bodey, and
E J Freireich
January 1980,
Cancer treatment reports,
V Rodriguez, and
S P Richman, and
R S Benjamin, and
M A Burgess, and
W K Murphy, and
M Valdivieso, and
R L Banner, and
J U Gutterman, and
G P Bodey, and
E J Freireich
December 1978,
Cancer treatment reports,
V Rodriguez, and
S P Richman, and
R S Benjamin, and
M A Burgess, and
W K Murphy, and
M Valdivieso, and
R L Banner, and
J U Gutterman, and
G P Bodey, and
E J Freireich
February 1982,
American journal of clinical oncology,
V Rodriguez, and
S P Richman, and
R S Benjamin, and
M A Burgess, and
W K Murphy, and
M Valdivieso, and
R L Banner, and
J U Gutterman, and
G P Bodey, and
E J Freireich
August 1986,
Cancer treatment reports,
V Rodriguez, and
S P Richman, and
R S Benjamin, and
M A Burgess, and
W K Murphy, and
M Valdivieso, and
R L Banner, and
J U Gutterman, and
G P Bodey, and
E J Freireich
June 1985,
Cancer treatment reports,
V Rodriguez, and
S P Richman, and
R S Benjamin, and
M A Burgess, and
W K Murphy, and
M Valdivieso, and
R L Banner, and
J U Gutterman, and
G P Bodey, and
E J Freireich
July 1978,
Biochemical and biophysical research communications,
